MAM
How digital technologies are reshaping pharma marketing in India
MUMBAI: India holds an important position in the global pharmaceutical sector. As per an IBEF report, it is the largest provider of generic drug globally and supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in the UK. However, marketing and advertising spends of pharmaceutical giants have been minimal for the past many decades, focusing mainly on B2B aspects of it and catered mainly through newspapers.
But the advent of digital technologies, social media, and a whole new culture of evolving direct marketing, marketers associated with pharmaceutical and healthcare industries in India are exploring new ways to reach out to not only business partners but consumers as well.
MedTrix Healthcare founder and CEO Vimal Narayan feels that doctors and patients both have become comfortable in accessing medical information on the internet, thus increasing the scope for healthcare and pharma marketers exponentially.
He says, “With the rise of chronic illness, increased per capita income, disease awareness, and immediate access to healthcare facilities, marketers in India have plenty to room to innovate. The traditional marketing channel and campaigns may not work due to the above-mentioned reasons and we need a specialised marketing strategy for each disease/therapy areas. For instance, up until 6-8 years ago, patients were not comfortable searching for doctors online, but they are comfortable now and the trend doesn’t seem to slow down. This simple example illustrates that both patients and physicians are online.”
This increasing scope of opportunities to innovate and scale a client’s business has pushed pharma & healthcare marketers to spend better and across platforms.
‘Healthcare Advertising Expenditure Forecasts 2019’ report by Zenith indicates that India is the fastest-growing market when it comes to spends on healthcare, surging at an average of 26 per cent a year between 2018 and 2021. The report also states that rising incomes and increased access to health insurance are making healthcare more accessible and encouraging a more direct-to-consumer marketing of healthcare products and services.
Publicis Worldwide MD Srija Chatterjee notes, “Traditionally pharma marketing was all of a nattily clad medical representative with glossy literature trying to impress upon the doctor. Over the years, this has changed to a much more complex process. Hyper-fragmentation of the market, breakdown of legacy models, patient empowerment and changing definition of care has brought in greater opportunities for marketers. A number of global brands losing patents have led to Indian generics competing at lower price points. MR time with doctor has gone below 30 seconds. Hence, there is more emphasis on 1:1 relationship, richer consumer behaviour, newer sales model design and newer points of engagements.”
Mirum general manager-sales Srikant Subramanian adds that there has been a tremendous growth from the digital perspective in Pharma marketing in India.
He says, “With the advent of social media, and digital in general, in this post-Jio world, we see a lot of fragmentation of core audiences of doctors, patients, and policymakers. As a result, contextual communication becomes a necessary tool, and there is larger scope for innovative, creative marketing to be done across the entire marketing sphere of digital, social, ATL as well as BTL.”
Surely, the growth of digital medium within the country has given birth to newer dimensions of healthcare and pharma business. Online platforms such as Curofy, DocPlexus, Practo, Medshr, Lybrate, Healtho5 Solutions, myhCue and Docquity are helping doctors communicate with their peers. Online pharmacies such as Netmeds, 1 mg, Pharmeasy are offering stiff competition to the traditional high street pharmacies. Then there are portals such as VEEVA and AGORA while knowledge dissemination portals such as ‘Knowledge Genie’ (Abbott) are the latest examples of tech affinity.
Narayan shares, “Digital transformation is revolutionising pharma and healthcare industry and is expected to transfigure medical communication strategies of pharma and healthcare companies. Some of the most preferred technologies adopted by companies are smart apps, patient chatbots, virtual assistants, virtual reality and augmented reality. These technologies seem to be the most preferred part of the go-to-market (GTM) strategy of pharma and healthcare companies in India and in the global markets. The way these technologies communicate with patients and physicians 24/7 is something that is widely appreciated.”
Another important change that has occurred in healthcare and pharma marketing in the country and across the globe, in the past few years, is that the lines between the language used for B2B and B2C marketing are blurring for good.
Subramanian quips, “Bryan Kramer puts it best when he said, that "It’s Human to Human H2H". The idea is that B2B is no longer about communicating from company to company, but person to person. We have to understand that need, and look to appeal to the emotional needs of our customers and how it relates to their business.”
He further adds that the only difference in communicating with these two sets of consumers lies in the scale and frequency of marketing depending on the audience.
“In our healthcare business, for OTC, we still need to drive awareness and availability of the store, as digital has still not become de-facto for purchase, so the application of your strategy will still need to appeal to a larger audience set. In a B2B scenario, however, the audience scale will always be smaller in comparison, and the messaging for individual audiences will be different basis their current stage in the buying cycle.”
Narayan insists that there has been a significant difference in approaches that marketers and companies adopt for B2B and B2C activities. He mentions that platforms like 1mg, Medlife, Practo, and Healthkart, etc, have used digital technology and communication methods to build B2C domains from scratch, which is very different from healthcare and pharma companies. The strategies adopted by pharma companies, in general, is driven by physician engagement level with other dynamics such as market growth rate, competition level, awareness matrix and so on.
“B2B marketing in this space is categorised under “One-Time Digital” solution and “Systematic Scalable Modular” solution. Many marketers prefer the latter, as they can replicate the model and fine-tune the marketing development plan at the execution stage year-on-year. At the same time, some pharma and healthcare clients prefer developing a custom Health CRM platform for their internal and external communication activities. This is an early sign of adoption of Systematic Scalable Modular solution, as you can integrate Medical Case player and email marketing along with Health CRM platform,” he elaborates.
Chatterjee also notes, “Communication in the health and pharma industry is complex. For one, it is heavily regulated, as it should be. Therefore, marketing to the consumer is largely on disease awareness, patient care, post-procedure maintenance care etc. For example, you can talk of diabetes and how to manage it, but you cannot advertise the drug because most of the complex drugs are ‘prescription only’.”
She further says, “To the HCP (health care professional) on the other hand, it is all about how they can help their patient. At the core of it, the communication is based on science – what the drug does, how the molecule can help, what research went into creating it, what studies were conducted on the drug and what were the outcomes and of course, advantages over a competitor drug. These are communicated through various channels, some borrowed from other industries like advertisements, information leaflets, etc. but more importantly, seminars, ISPs (international speaker programmes), camps. There has been a lot more adoption of digital channels in recent years.”
Marketers can fine-tune their strategies further using the heaps and bounds of data available online to strengthen their core strategies and curate personalised solutions for their respective audiences.
Brands
Zscaler, Airtel launch India AI Cyber Research Centre
New hub to boost cyber resilience and trusted AI use
NEW DELHI: As India’s digital engine roars ahead, so do the risks riding shotgun. In response, Zscaler, Inc. and Bharti Airtel have joined hands to launch the AI and Cyber Threat Research Center – India, a national initiative aimed at strengthening the country’s cyber defences and accelerating responsible AI adoption.
The centre is designed as a multi stakeholder platform that brings together industry, government and academia. Its mission is clear: protect critical sectors such as telecom, banking and energy, shield everyday digital users, and future proof India’s fast expanding online ecosystem.
India has long been a major innovation hub for Zscaler, with a substantial portion of its cyber research talent based here. With this new centre, that footprint evolves into a national collaboration engine. The idea is simple but ambitious, build in India, for India, and help power the country’s journey towards a secure and digitally self reliant future.
The timing is telling. India is building digital systems at population scale, not just enterprise scale. That scale has widened the attack surface dramatically. At the same time, cyber criminals and nation state actors are deploying AI to scan, probe and exploit vulnerabilities in minutes.
Zscaler’s research arm, ThreatLabz India, reports millions of infiltration attempts every month. These include espionage campaigns linked to regional geopolitical tensions, 1.2 million intrusion attempts from 20,000 sources targeting 58 Indian digital entities, and a rise in zero day exploit attempts across multiple industries.
In such an environment, perimeter based security models are struggling to keep pace. The new centre aims to push a shift towards secure by design systems and Zero Trust architecture.
Its strategy rests on four pillars: protect through real time intelligence, remediate by working directly with government agencies, facilitate adoption of AI driven security and Zero Trust frameworks, and build a stronger cybersecurity talent pipeline through specialised certifications.
As founding members, Zscaler and Airtel will combine global threat intelligence with local network visibility. Zscaler will deploy a dedicated India focused research team and draw insights from its Zero Trust Exchange platform, which processes over 500 billion daily transactions worldwide. Airtel, meanwhile, will contribute deep visibility into IoT and mobile traffic, helping detect suspicious activity faster and coordinate response across the ecosystem.
Bharti Airtel executive vice chairman Gopal Vittal, said the partnership extends Airtel’s commitment to safeguarding customers and the nation’s digital fabric. He added that the collaboration would address challenges unique to the Indian market and encourage secure and confident digital engagement.
Zscaler chief executive, chairman and founder Jay Chaudhry, said India’s digital ambition cannot be secured with legacy firewalls and VPNs. He noted that a modern Zero Trust architecture is essential for a hyper connected world and that the new centre would harness the scale of Zscaler’s global security cloud while empowering a new generation of Indian cyber defenders.
Additional members from critical public and private sectors are expected to join the initiative in the coming months, expanding its scope and deepening collaboration.
In a world where threats travel at machine speed, India’s answer is to think faster, collaborate wider and build smarter.
